/
Ophthalmology
Eye Disease
23
Pipeline Programs↗
19
Active Trials↗
38
Companies Involved↗
Eye Disease is an emerging landscape with 23 programs across 38 companies. The most active players are Apellis Pharmaceuticals, Telios Pharma, Inc., Bayer. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical18
Phase 21
Phase 33
Approved
No programs
Analysis
Modality Breakdown
87%
Small molecule
20 of 23 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.
Analysis
Trial Status
206
clinical trials
Completed149 · 72%
Unknown status22 · 11%
Recruiting11 · 5%
Terminated9 · 4%
Withdrawn6 · 3%
Not yet recruiting4 · 2%
Other5 · 2%
Clinical Trials
Trial Activity
206 trials
Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease
Recruiting·—·Phase 2·NCT04673643·128 enrolled
Salivary Conductivity Screening for Dry Eye Disease and Sjögren's Syndrome
Recruiting·—·N/A·NCT06406933·200 enrolled
Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease With Meibomian Gland Dysfunction
Recruiting·—·Phase 1/2·NCT06544447·135 enrolled
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
Active, not recruiting·—·Phase 3·NCT06329791·500 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)